Skip to main content
Midas Edge

C4 Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

CCCC$3.15+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statement of Stockholder’s Equity

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensive Income (Loss) · Accumulated Deficit · TotalStockholders' Equity
Shares · Amount
Balance as of December 31, 202470,625,899$7$849,62553$(633,699)$215,986
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding321,342(155)—(155)
Issuance of common stock under 2020 ESPP35,589109—109
Stock-based compensation5,507—5,507
Change in unrealized loss, net on marketable securities———(10)—(10)
Net loss————(26,322)(26,322)
Other6,831—25——25
Balance as of March 31, 202570,989,661$7$855,111$43$(660,021)$195,140
Stock-based compensation——4,992——4,992
Change in unrealized loss, net on marketable securities———(73)—(73)
Net loss————(26,020)(26,020)
Other17,422—25——25
Balance as of June 30, 202571,007,083$7$860,128$(30)$(686,041)$174,064
Issuance of common stock pursuant to the at-the-market equity program, net2,950,225—7,526——7,526
Exercise of stock options and release of stock units50,000—107——107
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding14,868—(24)——(24)
Issuance of common stock under 2020 ESPP135,114—164——164
Stock-based compensation——4,593——4,593
Change in unrealized loss, net on marketable securities———117—117
Net loss————(32,166)(32,166)
Other17,225—27——27
Balance as of September 30, 202574,174,515$7$872,521$87$(718,207)$154,408
Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount
Balance as of December 31, 202360,467,188$6$774,618$(127)$(528,383)$246,114
Issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement5,567,928119,999——20,000
Issuance of common stock pursuant to the at-the-market equity program, net2,500,601—14,089——14,089
Issuance of common stock upon exercise of stock options80,936—519——519
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding121,516—(109)——(109)
Issuance of common stock under 2020 ESPP34,902—84——84
Stock-based compensation——6,215——6,215
Change in unrealized loss, net on marketable securities———(253)—(253)
Net loss————(28,361)(28,361)
Other5,520—(16)——(16)
Balance as of March 31, 202468,778,591$7$815,399$(380)$(556,744)$258,282
Exercise of stock options and release of stock units32,607—135——135
Stock-based compensation——6,381——6,381
Change in unrealized loss, net on marketable securities———(60)—(60)
Net loss————(17,716)(17,716)
Other4,444—36——36
Balance as of June 30, 202468,815,642$7$821,951$(440)$(574,460)$247,058
Issuance of common stock pursuant to the at-the-market equity program, net1,631,521—10,280——10,280
Exercise of stock options and release of stock units1,714—13——13
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding31,363—(85)——(85)
Issuance of common stock under 2020 ESPP75,993—298——298
Stock-based compensation——8,831——8,831
Change in unrealized loss, net on marketable securities———895—895
Net loss————(24,666)(24,666)
Other6,668—32——32
Balance as of September 30, 202470,562,901$7$841,320$455$(599,126)$242,656
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.